BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 8208494)

  • 1. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
    Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surfactant therapy in respiratory distress syndrome--the first local experience.
    Lim NL; Nordin MM; Cheah IG
    Med J Malaysia; 1994 Mar; 49(1):4-11. PubMed ID: 8057989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.
    Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.
    Corbet A; Bucciarelli R; Goldman S; Mammel M; Wold D; Long W
    J Pediatr; 1991 Feb; 118(2):277-84. PubMed ID: 1993961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity.
    Modanlou HD; Beharry K; Padilla G; Norris K; Safvati S; Aranda JV
    J Perinatol; 1997; 17(6):455-60. PubMed ID: 9447532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Natural and synthetic surfactant in the treatment of neonatal respiratory distress syndrome].
    Bratlid D; Farstad T
    Tidsskr Nor Laegeforen; 1994 Jan; 114(1):33-6. PubMed ID: 8296279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant.
    Corbet AJ; Long WA; Murphy DJ; Garcia-Prats JA; Lombardy LR; Wold DE
    J Paediatr Child Health; 1991 Aug; 27(4):245-9. PubMed ID: 1958425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.
    da Costa DE; Pai MG; Al Khusaiby SM
    Pediatr Pulmonol; 1999 May; 27(5):312-7. PubMed ID: 10344709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effects of surfactant therapy for neonatal respiratory distress syndrome.
    Phibbs CS; Phibbs RH; Wakeley A; Schlueter MA; Sniderman S; Tooley WH
    J Pediatr; 1993 Dec; 123(6):953-62. PubMed ID: 8229530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome.
    Hudak ML; Farrell EE; Rosenberg AA; Jung AL; Auten RL; Durand DJ; Horgan MJ; Buckwald S; Belcastro MR; Donohue PK; Carrion V; Maniscalco WW; Balsan MJ; Torres BA; Miller RR; Jansen RD; Graeber JE; Laskay KM; Matteson EJ; Egan EA; Brody AS; Martin DJ; Riddlesberger MM; Montgomery P
    J Pediatr; 1996 Mar; 128(3):396-406. PubMed ID: 8774514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I.
    Long W; Thompson T; Sundell H; Schumacher R; Volberg F; Guthrie R
    J Pediatr; 1991 Apr; 118(4 Pt 1):595-605. PubMed ID: 2007938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment.
    Bhutani VK; Bowen FW; Sivieri EM
    Biol Neonate; 2005; 87(4):323-31. PubMed ID: 15985755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome.
    Easa D; Pelke S; Nakamura KT; Barrett J; Balaraman V; Loo SW; Ibarra-Pratt E; Smith MB
    Pediatr Pulmonol; 1992 Sep; 14(1):16-22. PubMed ID: 1437338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant.
    Bose C; Corbet A; Bose G; Garcia-Prats J; Lombardy L; Wold D; Donlon D; Long W
    J Pediatr; 1990 Dec; 117(6):947-53. PubMed ID: 2246698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.